Glenmark Pharmaceuticals Limited Share Price & Stock Analysis

Glenmark Pharmaceuticals Limited (NSE: GLENMARK, BSE: 532296) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹75,556 Cr, it ranks #148 by market cap among the 6,197 Indian listed companies on FinBizNet, and #9 of 86 in Medicinal Chemicals and Botanical Products. At ₹2,640.00 (as of 16 Nov 2026), the share price is 2.7% below its 52-week high of ₹2,714.00 and 45.9% above its 52-week low of ₹1,810.00. The share price is up 45.7% over one year and up 13.8% over three months.

Key Metrics

Current Price₹2,640.00
Market Cap₹75,556 Cr
NSE SymbolGLENMARK
BSE Code532296
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E Ratio55.1
Return on Equity14.07%
Return on Assets14.11%
52-Week Range₹1,810.00 – ₹2,714.00
1-Year Price Change+45.7%
3-Month Price Change+13.8%
Beta (1Y)0.23
Dividend Yield0.19%
HeadquartersMumbai, Maharashtra
Websiteglenmarkpharma.com

Latest Quarterly Results — Q2 FY27

Revenue₹4,157 Cr
Net Profit₹264 Cr
Net Margin6.3%
EPS (Basic)₹9.35
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Glenmark Pharmaceuticals Limited Quarterly Revenue and Profit Trend

Glenmark Pharmaceuticals Limited reported revenue of ₹4,157 Cr in Q2 FY27, down 31.3% from ₹6,047 Cr in Q2 FY26 and up 3.4% from ₹4,018 Cr in Q1 FY27. It posted a net profit of ₹264 Cr for the quarter, against a net profit of ₹610 Cr in Q2 FY26 (down 56.8%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹3,256 Cr (Q4 FY25) to ₹6,047 Cr (Q2 FY26). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹4,157 Cr₹264 Cr6.3%
Q1 FY27₹4,018 Cr₹483 Cr12.0%
Q4 FY26₹3,771 Cr₹301 Cr8.0%
Q3 FY26₹3,901 Cr₹403 Cr10.3%
Q2 FY26₹6,047 Cr₹610 Cr10.1%
Q1 FY26₹3,264 Cr₹47 Cr1.4%
Q4 FY25₹3,256 Cr₹4 Cr0.1%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 46.65% of Glenmark Pharmaceuticals Limited's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 45.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 TREAT trispecific T cell engager, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 2301, a NK cell engager that is in preclinical trial for solid tumors; and GRC 65327, a Cbl-b inhibitor small molecule for

Products and Services

1. Pharmaceuticals-This segment develops, manufactures, and markets pharmaceutical products. It provides active pharmaceutical ingredients in the therapeutic areas of alimentary track, anti-infective, anti-parasitic, cardiovascular, central nervous system, dermatological, genito-urinary, musculo-skeletal, respiratory, and others; and formulations in the therapeutic areas of dermatology, respiratory, cardiovascular, anti- diabetic, and oncology.

Business Segments

1. Pharmaceuticals-100%

Glenmark Pharmaceuticals Limited vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Glenmark Pharmaceuticals Limited₹75,556 Cr55.114.07%₹4,157 Cr+45.7%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Glenmark Pharmaceuticals Limited?

Glenmark Pharmaceuticals Limited is trading at ₹2,640.00, with a market capitalisation of ₹75,556 Cr.

Which sector does Glenmark Pharmaceuticals Limited belong to?

Glenmark Pharmaceuticals Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Glenmark Pharmaceuticals Limited?

Glenmark Pharmaceuticals Limited has a P/E of 55.1 and a return on equity of 14.07%.

What is the stock symbol of Glenmark Pharmaceuticals Limited?

Glenmark Pharmaceuticals Limited is listed on the NSE under the symbol GLENMARK and on the BSE under the scrip code 532296.

How has Glenmark Pharmaceuticals Limited's share price moved over the past year?

Glenmark Pharmaceuticals Limited's share price is up 45.7% over one year and up 13.8% over three months. Its 52-week range is ₹1,810.00 to ₹2,714.00.

What were Glenmark Pharmaceuticals Limited's latest quarterly results?

In Q2 FY27, Glenmark Pharmaceuticals Limited reported revenue of ₹4,157 Cr and net profit of ₹264 Cr, with basic EPS of ₹9.35 (consolidated, parsed from the company's exchange filing).

How have Glenmark Pharmaceuticals Limited's revenue and profit changed over the past year?

Glenmark Pharmaceuticals Limited reported revenue of ₹4,157 Cr in Q2 FY27, down 31.3% from ₹6,047 Cr in Q2 FY26 and up 3.4% from ₹4,018 Cr in Q1 FY27.

What is the promoter holding in Glenmark Pharmaceuticals Limited?

Promoters held 46.65% of Glenmark Pharmaceuticals Limited's shares as of Sept 2026, unchanged from Sept 2025.

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.